TSO3 - News Feed http://tso3.com/ TSO3 Announces the Death of Mr. Jean Lamarre Quebec City, Canada and Myrtle Beach, United States, November 27, 2017 – TSO3 Inc. (TSX: TOS), sadly announced the death of Mr. Jean Lamarre, a member of the Board of Directors of TSO3.  Mr. Lamarre contributed sound and constructive counsel on TSO3’s Board of Directors, and while leading TSO3’s Human Resources Committee. Mr. Lamarre was a pillar of the Canadian business community, holding several board positions, including the position of Board Chair for SEMAFO, and various other positions of significant responsibility with Groupe Lavalin and numerous other organizations. 2017-11-27 00:00:00 http://tso3.com/en/news_events/article/200 TSO3 Provides Duodenoscope Regulatory Filing Update Quebec City, Canada and Myrtle Beach, United States, November 16, 2017 – TSO3 Inc. (TSX: TOS)nnounced today that it has responded to the recent request for additional information (AI), from the U.S. Food and Drug Administration. This information is in support of the Company’s submission to extend claims of its innovative STERIZONE® VP4 Sterilizer to include terminal sterilization of duodenoscopes. 2017-11-16 00:00:00 http://tso3.com/en/news_events/article/199 TSO3 Reports Record Third Quarter 2017 Results Quebec City, Canada and Myrtle Beach, United States, November 6, 2017 – TSO3 Inc. (TSX: TOS) reported financial results for its third fiscal quarter 2017 ended September 30, 2017.   2017-11-06 00:00:00 http://tso3.com/en/news_events/article/197 TSO3 Sets Third Quarter Earnings Call for Tuesday, November 7, 2017 at 8:30 a.m. EST Québec City, Canada and Myrtle Beach, United States of America, October 25, 2017 – TSO3 Inc. (TSX: TOS) will hold a conference call on Tuesday, November 7, 2017, to discuss its financial results for the third quarter ended September 30, 2017. Financial results will be issued in a press release prior to the call. 2017-10-25 00:00:00 http://tso3.com/en/news_events/article/196 TSO3 Duodenoscope Sterilization Technology to be Featured at the 18th World Federation for Hospital Sterilisation Sciences (WFHSS) Congress in Bonn, Germany Quebec City, Canada and Myrtle Beach, United States, October 3, 2017 – TSO3 Inc. (TSX: TOS) today announced that Mr. Albert Csapo, BA, Manager, Medical Device Reprocessing Department, Vancouver General Hospital (VGH), the University of British Columbia Hospital (UBCH), and satellites at GLDHCC, ECC, and Endoscopy, shall give a presentation titled “Sterilization of endoscopes and why we chose a low-temperature reprocessing method” on Friday, October 6th during the 18th WFHSS Congress in Bonn, Germany.  2017-10-03 00:00:00 http://tso3.com/en/news_events/article/195 TSO3 Provides an Update on Regulatory Activity Quebec City, Canada and Myrtle Beach, United States, September 27, 2017 – TSO3 Inc. (TSX: TOS) today announced that the Company has received correspondence from US regulators pertaining to its submission for extended claims for the STERIZONE® VP4 Sterilizer in relation to the terminal sterilization of duodenoscopes, which are used in endoscopic retrograde cholangio-pancreatography (ERCP) procedures.    2017-09-27 00:00:00 http://tso3.com/en/news_events/article/194 TSO3 Appoints Dr. Bradley J. Catalone as Chief Science Officer Quebec City, Canada and Myrtle Beach, United States, September 25, 2017 – TSO3 Inc. (TSX: TOS) today announced that Dr. Bradley J. Catalone MBA, Ph.D. has joined TSO3 as its Chief Science Officer. 2017-09-25 00:00:00 http://tso3.com/en/news_events/article/193 TSO3 Provides an Update on Recent Activities Quebec City, Canada and Myrtle Beach, United States, September 7, 2017 – TSO3 Inc. (TSX: TOS) today announced that a major hospital in Canada has initiated terminal sterilization of duodenoscopes with the Company’s STERIZONE® VP4 Sterilizer.  Additionally, the Company has successfully completed both a Quality System compliance inspection by US regulators and four weeks of comprehensive sales and marketing training with personnel from its exclusive distribution partner, the Getinge Group.  2017-09-07 00:00:00 http://tso3.com/en/news_events/article/192 TSO3 Comments on Unusual Trading Activities Québec City, Canada and Myrtle Beach, United States, August 23, 2017 – TSO3 Inc. (TSX: TOS) announced today, at the request of the Investment Industry Regulatory Organization of Canada (IIROC), that it is not aware of any undisclosed material change to the Corporation's business or operations that would cause today's unusual trading activities in the Corporation's stock and has no material change to report at this time. 2017-08-23 00:00:00 http://tso3.com/en/news_events/article/191 TSO3 Reports Record Second Quarter 2017 Results Quebec City, Canada and Myrtle Beach, United States, August 1,  2017 – TSO3 Inc. (TSX: TOS) reported financial results for its second fiscal quarter 2017 ended June 30, 2017. 2017-08-01 00:00:00 http://tso3.com/en/news_events/article/190 TSO3 Sets Second Quarter Earnings Call for Wednesday, August 2, 2017 at 8:30 a.m. EDT Québec City, July 24, 2017 – TSO3 Inc. (TSX: TOS) will hold a conference call on Wednesday, August 2, 2017, to discuss its financial results for the second quarter ended June 30, 2017. Financial results will be issued in a press release prior to the call. 2017-07-24 00:00:00 http://tso3.com/en/news_events/article/189 TSO3 Files for an Extended Claim for Duodenoscopes Quebec City, Canada and Myrtle Beach, United States, July 20 2017 – TSO3 Inc. (TSX: TOS) today announced that the Company has filed a 510(k) submission with US regulators for its STERIZONE® VP4 Sterilizer for the terminal sterilization of duodenoscopes used in endoscopic retrograde cholangio-pancreatography (ERCP) procedures.  If awarded such claim, TSO3’s STERIZONE® VP4 Sterilizer would become the first and only validated sterilizer technology in the US with a cleared label claim for the terminal sterilization of duodenoscopes.   2017-07-20 00:00:00 http://tso3.com/en/news_events/article/188 TSO3 Expands Duodenoscope Regulatory Filing Strategy Quebec City, Canada and Myrtle Beach, United States, June 14, 2017 – TSO3 Inc. (TSX: TOS) today announced that the Company now plans to seek 510(k) clearance for its STERIZONE® VP4 Sterilizer from US regulators for the terminal sterilization of the two duodenoscopes used in the majority of endoscopic retrograde cholangio-pancreatography (ERCP) procedures performed globally. 2017-06-14 00:00:00 http://tso3.com/en/news_events/article/187 TSO3 announces the Vote Results from its Annual Meeting of the Shareholders Québec City, May 11, 2017 – TSO3 Inc. (TSX: TOS) today announced that the nominees listed in the management proxy circular dated April 4, 2017, were elected as directors of TSO3. In addition, all other proposals submitted by management were approved. 2017-05-11 00:00:00 http://tso3.com/en/news_events/article/186 TSO3 Reports Record First Quarter 2017 Results Quebec City, May 10, 2017 – TSO3 Inc. (TSX: TOS) reported financial results for its first fiscal quarter 2017 ended March 31, 2017. 2017-05-10 06:30:00 http://tso3.com/en/news_events/article/185 TSO3 to Report First Quarter 2017 Results and Hold Annual Meeting of Shareholders on Wednesday, May 10, 2017 Quebec City, April 26, 2017 – TSO3 Inc. (TSX: TOS) will report financial results for its first fiscal quarter 2017 ended March 31, 2017.  Financial results will be issued in a press release on May 10, prior to the meeting. 2017-04-26 00:00:00 http://tso3.com/en/news_events/article/184 TSO3 to publish innovative validation method linked to sterilization of multichannel endoscopes in upcoming issue of the Canadian Journal of Infection Control Québec City, Canada/Myrtle Beach, USA, April 19, 2017 – TSO3 Inc. (TSX: TOS) announced today that an original paper has been accepted for publication in the peer-reviewed Canadian Journal of Infection Control.  The paper describes the first and only gravity based direct inoculation (intentional bacterial contamination) method which meets the requirements of US regulators for confirmation that the inoculum is deposited into the middle of each channel of complex multichannel endoscopes.  Additionally, the paper describes the TSO3 STERIZONE® low temperature sterilization system and its ability to sterilize such scopes. 2017-04-19 00:00:00 http://tso3.com/en/news_events/article/183 TSO3 Reports Record Fourth Quarter and Full Year 2016 Results Québec City, March 21, 2017 – TSO3 Inc. (TSX: TOS) ("TSO3" or the "Company") reported its operating results for the fourth quarter and year ended December 31, 2016. All figures are in US dollars unless otherwise noted. 2017-03-21 00:00:00 http://tso3.com/en/news_events/article/182 TSO3 Sets Fourth Quarter and Full Year 2016 Earnings Call for Tuesday, March 21, 2017 at 10:30 a.m. EDT Québec City, March 7, 2017 – TSO3 Inc. (TSX: TOS) will hold a conference call on Tuesday, March 21, 2017, to discuss its financial results for the fourth quarter and full year ended December 31, 2016. Financial results will be issued in a press release prior to the call. 2017-03-07 00:00:00 http://tso3.com/en/news_events/article/181 TSO3 Appoints Dr. Linda Rosenstock and Mr. Jeffrey Pompeo to its Board of Directors Québec City, Québec – February 16, 2017 – The board of directors of TSO3 Inc. (TSX: TOS) has appointed Dr. Linda Rosenstock and Mr. Jeffrey Pompeo as additional members to the Company’s board of directors.     2017-02-16 08:26:00 http://tso3.com/en/news_events/article/180 TSO3 Appoints Mark Pasmore as Vice President of Research and Development Québec City, Québec – February 2, 2017 – TSO3 Inc. (TSX: TOS) ("TSO3" or the "Company") has named Dr. Mark Pasmore Ph.D. as Vice President of Research and Development. 2017-02-02 04:00:00 http://tso3.com/en/news_events/article/179 TSO3 Welcomes The Medical University of South Carolina to its Strategic Partner Facility Program QUÉBEC CITY, January 26, 2017  - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Company") announced yesterday that MUSC Health, which is the clinical enterprise of the Medical University of South Carolina, has joined its Strategic Partner Facility Program. 2017-01-26 06:36:00 http://tso3.com/en/news_events/article/178 TSO3 Provides an Operational Update Québec City, Québec – January 5, 2017 – TSO3 Inc. (TSX: TOS) ("TSO3" or the "Company") today provided an update on its 2016 operating activities ahead of an Analyst Day which the Company is holding today in Myrtle Beach, South Carolina. 2017-01-05 07:30:00 http://tso3.com/en/news_events/article/176 TSO3 adds the University of Rochester Medical Center to its Strategic Partner Facility Program Québec City, Québec – January 5, 2017 – TSO3 Inc. (TSX: TOS) ("TSO3" or the "Company")announced today that Highland Hospital of Rochester, NY (“the Hospital”), which is part of UR Medicine, the University of Rochester’s clinical enterprise, has joined its Strategic Partner Facility Program. 2017-01-05 07:00:00 http://tso3.com/en/news_events/article/175